No Cover Image

Journal article 552 views 59 downloads

Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19

Helen Yu

INQUIRY: The Journal of Health Care Organization, Provision, and Financing, Volume: 58, Start page: 004695802110597

Swansea University Author: Helen Yu

  • 64383.VOR.pdf

    PDF | Version of Record

    © The Author(s) 2021. Distributed under the terms of a Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0).

    Download (565.75KB)

Check full text

DOI (Published version): 10.1177/00469580211059734

Abstract

In response to the COVID-19 pandemic, significant public funds have been invested worldwide into the research, development, and manufacturing of pharmaceutical products to combat the novel coronavirus. Traditionally, intellectual property (IP) rights have been justified in the pharmaceutical sector...

Full description

Published in: INQUIRY: The Journal of Health Care Organization, Provision, and Financing
ISSN: 0046-9580 1945-7243
Published: SAGE Publications 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa64383
first_indexed 2023-10-17T14:18:47Z
last_indexed 2024-11-25T14:13:56Z
id cronfa64383
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2023-10-17T15:20:49.1551556</datestamp><bib-version>v2</bib-version><id>64383</id><entry>2023-09-04</entry><title>Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19</title><swanseaauthors><author><sid>3fa8e58607d4949e7d0d3fa8fa1c2f7d</sid><firstname>Helen</firstname><surname>Yu</surname><name>Helen Yu</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-09-04</date><deptcode>CBAE</deptcode><abstract>In response to the COVID-19 pandemic, significant public funds have been invested worldwide into the research, development, and manufacturing of pharmaceutical products to combat the novel coronavirus. Traditionally, intellectual property (IP) rights have been justified in the pharmaceutical sector because of the time and cost associated with drug discovery and development. However, if (a) the cost of research for COVID-19 related innovations have largely been subsidized by the public through public research grants; (b) the time for development has been significantly reduced through publicly funded initiatives; and (c) manufacturing has been de-risked through taxpayer funded advance purchase agreements, should IP rights be asserted on innovations that have largely already been paid for by the public?. There needs to be clear legal and regulatory frameworks, informed by policy objectives such as principles of &#x201C;responsible research and innovation&#x201D; and &#x201C;global public good,&#x201D; to ensure that outcomes of publicly funded efforts can ultimately reach the intended public. Without any access and production conditions associated with the use of public efforts, worldwide supplies to medical solutions that benefited from these public initiatives can be frustrated. This article proposes a legal framework to address future access and availability problems to medical innovations that benefit from publicly funded initiatives.</abstract><type>Journal Article</type><journal>INQUIRY: The Journal of Health Care Organization, Provision, and Financing</journal><volume>58</volume><journalNumber/><paginationStart>004695802110597</paginationStart><paginationEnd/><publisher>SAGE Publications</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0046-9580</issnPrint><issnElectronic>1945-7243</issnElectronic><keywords>Return of benefit to society, responsible research and sustainable innovation, health policy and pandemic preparedness, legally supported framework for access and availability to healthcare, conditional access to publicly funded initiatives</keywords><publishedDay>1</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-01-01</publishedDate><doi>10.1177/00469580211059734</doi><url>http://dx.doi.org/10.1177/00469580211059734</url><notes/><college>COLLEGE NANME</college><department>Management School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>CBAE</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This article was supported by Novo Nordisk Fonden (grant no. NNF17SA0027784) and Centre for Digital Life Norway (grant no. 294594).</funders><projectreference/><lastEdited>2023-10-17T15:20:49.1551556</lastEdited><Created>2023-09-04T15:05:24.2046132</Created><path><level id="1">Faculty of Humanities and Social Sciences</level><level id="2">School of Management - Business Management</level></path><authors><author><firstname>Helen</firstname><surname>Yu</surname><order>1</order></author></authors><documents><document><filename>64383__28802__f841231d7e2041088eba482bcc8b420b.pdf</filename><originalFilename>64383.VOR.pdf</originalFilename><uploaded>2023-10-17T15:19:53.1045111</uploaded><type>Output</type><contentLength>579330</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The Author(s) 2021. Distributed under the terms of a Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2023-10-17T15:20:49.1551556 v2 64383 2023-09-04 Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19 3fa8e58607d4949e7d0d3fa8fa1c2f7d Helen Yu Helen Yu true false 2023-09-04 CBAE In response to the COVID-19 pandemic, significant public funds have been invested worldwide into the research, development, and manufacturing of pharmaceutical products to combat the novel coronavirus. Traditionally, intellectual property (IP) rights have been justified in the pharmaceutical sector because of the time and cost associated with drug discovery and development. However, if (a) the cost of research for COVID-19 related innovations have largely been subsidized by the public through public research grants; (b) the time for development has been significantly reduced through publicly funded initiatives; and (c) manufacturing has been de-risked through taxpayer funded advance purchase agreements, should IP rights be asserted on innovations that have largely already been paid for by the public?. There needs to be clear legal and regulatory frameworks, informed by policy objectives such as principles of “responsible research and innovation” and “global public good,” to ensure that outcomes of publicly funded efforts can ultimately reach the intended public. Without any access and production conditions associated with the use of public efforts, worldwide supplies to medical solutions that benefited from these public initiatives can be frustrated. This article proposes a legal framework to address future access and availability problems to medical innovations that benefit from publicly funded initiatives. Journal Article INQUIRY: The Journal of Health Care Organization, Provision, and Financing 58 004695802110597 SAGE Publications 0046-9580 1945-7243 Return of benefit to society, responsible research and sustainable innovation, health policy and pandemic preparedness, legally supported framework for access and availability to healthcare, conditional access to publicly funded initiatives 1 1 2021 2021-01-01 10.1177/00469580211059734 http://dx.doi.org/10.1177/00469580211059734 COLLEGE NANME Management School COLLEGE CODE CBAE Swansea University This article was supported by Novo Nordisk Fonden (grant no. NNF17SA0027784) and Centre for Digital Life Norway (grant no. 294594). 2023-10-17T15:20:49.1551556 2023-09-04T15:05:24.2046132 Faculty of Humanities and Social Sciences School of Management - Business Management Helen Yu 1 64383__28802__f841231d7e2041088eba482bcc8b420b.pdf 64383.VOR.pdf 2023-10-17T15:19:53.1045111 Output 579330 application/pdf Version of Record true © The Author(s) 2021. Distributed under the terms of a Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0). true eng https://creativecommons.org/licenses/by-nc/4.0/
title Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
spellingShingle Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
Helen Yu
title_short Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
title_full Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
title_fullStr Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
title_full_unstemmed Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
title_sort Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
author_id_str_mv 3fa8e58607d4949e7d0d3fa8fa1c2f7d
author_id_fullname_str_mv 3fa8e58607d4949e7d0d3fa8fa1c2f7d_***_Helen Yu
author Helen Yu
author2 Helen Yu
format Journal article
container_title INQUIRY: The Journal of Health Care Organization, Provision, and Financing
container_volume 58
container_start_page 004695802110597
publishDate 2021
institution Swansea University
issn 0046-9580
1945-7243
doi_str_mv 10.1177/00469580211059734
publisher SAGE Publications
college_str Faculty of Humanities and Social Sciences
hierarchytype
hierarchy_top_id facultyofhumanitiesandsocialsciences
hierarchy_top_title Faculty of Humanities and Social Sciences
hierarchy_parent_id facultyofhumanitiesandsocialsciences
hierarchy_parent_title Faculty of Humanities and Social Sciences
department_str School of Management - Business Management{{{_:::_}}}Faculty of Humanities and Social Sciences{{{_:::_}}}School of Management - Business Management
url http://dx.doi.org/10.1177/00469580211059734
document_store_str 1
active_str 0
description In response to the COVID-19 pandemic, significant public funds have been invested worldwide into the research, development, and manufacturing of pharmaceutical products to combat the novel coronavirus. Traditionally, intellectual property (IP) rights have been justified in the pharmaceutical sector because of the time and cost associated with drug discovery and development. However, if (a) the cost of research for COVID-19 related innovations have largely been subsidized by the public through public research grants; (b) the time for development has been significantly reduced through publicly funded initiatives; and (c) manufacturing has been de-risked through taxpayer funded advance purchase agreements, should IP rights be asserted on innovations that have largely already been paid for by the public?. There needs to be clear legal and regulatory frameworks, informed by policy objectives such as principles of “responsible research and innovation” and “global public good,” to ensure that outcomes of publicly funded efforts can ultimately reach the intended public. Without any access and production conditions associated with the use of public efforts, worldwide supplies to medical solutions that benefited from these public initiatives can be frustrated. This article proposes a legal framework to address future access and availability problems to medical innovations that benefit from publicly funded initiatives.
published_date 2021-01-01T05:15:02Z
_version_ 1851097038343634944
score 11.089386

Similar Items